Vanda Pharmaceuticals (VNDA) Raw Materials (2014 - 2015)
Vanda Pharmaceuticals' (VNDA) quarterly Raw Materials came in at $128000.0 in Q3 2015, down 39.91% year-on-year from $213000.0 in Q3 2014, and little changed quarter-over-quarter from $128000.0 in Q2 2015.
Vanda Pharmaceuticals (VNDA) Raw Materials (2014 - 2015) Analysis & Trends
Vanda Pharmaceuticals has disclosed Raw Materials across 2 years of filings, most recently posting $128000.0 for Q3 2015.
- Raw Materials for Q3 2015 came in at $128000.0, down 39.91% year-over-year; the trailing twelve-month figure through Sep 2015 was $128000.0 (down 39.91% YoY), and the FY2014 annual result was $198000.0, changed N/A from the prior year.
- Raw Materials came in at $128000.0 for Q3 2015 at Vanda Pharmaceuticals, roughly flat from $128000.0 in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $213000.0 in Q3 2014 to a low of $128000.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Vanda Pharmaceuticals | 345.46 Mn | 143.15 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 128,000.00 |
| Jun 30, 2015 | 128,000.00 |
| Mar 31, 2015 | 162,000.00 |
| Dec 31, 2014 | 198,000.00 |
| Sep 30, 2014 | 213,000.00 |
| Jun 30, 2014 | 145,000.00 |
| Mar 31, 2014 | 143,000.00 |